The FDA has issued a Complete Response Letter (CRL) to Correvio Pharma regarding the NDA for Brinavess for the conversion of atrial fibrillation.
Left atrial enlargement with vs without atrial fibrillation was not found to be associated with greater cognitive decline over a 5-year period.
The efficacy at 1 year of pulmonary vein isolation after atrial fibrillation ablation was found to be comparable when using radiofrequency ablation guided by tissue contact-force and cryoballoon ablation.
Evidence on strategies for identifying new atrial fibrillation after stroke is summarized by the AF-SCREEN International Collaboration.
Investigators report cardiac arrhythmias with or without apnea among patients with epilepsy are associated with increased mortality risk.
According to recent estimates from the Centers for Disease Control and Prevention, stroke affects more than 795,000 individuals in the United States annually and represents the fifth leading cause of death in the country.1 Stroke is also associated with substantial long-term disability and with costs estimated at $34 billion each year. Atrial fibrillation (AF), which…
For patients aged 65 years or older with atrial fibrillation, receipt of a prescription for an oral anticoagulant in the emergency department is associated with increased use of oral anticoagulants at six months.
The incidence of patients who are not responsive to cardiac resynchronization therapy was found to be high.
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 2 to 11 against the approval of Brinavess for the rapid conversion of recent onset atrial fibrillation.
The use of nonsteroidal anti-inflammatory drugs in patients with atrial fibrillation was found to be associated with an increased risk for major and clinically relevant nonmajor bleeding.